CN112730714A - Method for measuring content uniformity of benidipine hydrochloride tablets - Google Patents
Method for measuring content uniformity of benidipine hydrochloride tablets Download PDFInfo
- Publication number
- CN112730714A CN112730714A CN201910973392.2A CN201910973392A CN112730714A CN 112730714 A CN112730714 A CN 112730714A CN 201910973392 A CN201910973392 A CN 201910973392A CN 112730714 A CN112730714 A CN 112730714A
- Authority
- CN
- China
- Prior art keywords
- benidipine hydrochloride
- measuring
- content uniformity
- phosphoric acid
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method for measuring content uniformity of a benidipine hydrochloride tablet, and solves the technical problems of poor discrimination, complex operation, long detection time and great influence on human health of the conventional method for measuring the content uniformity of the benidipine hydrochloride tablet. The invention provides a method for measuring content uniformity of benidipine hydrochloride tablets, which comprises the following steps: taking 1 tablet of benidipine hydrochloride, placing in a 100ml measuring flask, adding a proper amount of methanol-diluted phosphoric acid mixed solution, ultrasonically dissolving and diluting benidipine hydrochloride to scale, shaking up, filtering, and taking the subsequent filtrate as a test solution. The method is widely applied to the detection of the content uniformity of the benidipine hydrochloride tablets.
Description
Technical Field
The invention relates to the technical field of pharmacy, in particular to a method for measuring content uniformity of benidipine hydrochloride tablets.
Background
Benidipine hydrochloride belongs to dihydropyridine calcium ion antagonists, and expands blood vessels by binding to dihydropyridine receptors that block cell membrane potential-dependent calcium ion channels, and preventing calcium ion influx into cells. Benidipine hydrochloride is widely used as a therapeutic drug for hypertension, renal essential hypertension, angina pectoris, and the like because it is safe and effective.
The content uniformity is a key parameter for evaluating the quality of the medicine and is also a key factor for examining the quality of the medicine according to the Chinese pharmacopoeia. The content is guaranteed for the whole batch of products, and the content uniformity is the difference between the content of each piece. However, the detection method has the following problems:
1. the existing method for measuring the content uniformity of the benidipine hydrochloride tablets in China is an ultraviolet method, and substances such as auxiliary materials and the like which have absorption at the wavelength influence the detection result, so that the interference factors are more, and the result accuracy is poor.
2. In the past, the content uniformity is detected by taking 1 sample, adding a solvent, grinding, and then quantitatively transferring to a volumetric flask to prepare a test solution. The traditional method has a complex operation process, the volatilization of organic solvents such as methanol and the like has great harm to the health of operators, and in addition, incomplete transfer also easily causes detection errors and inaccurate results.
3. The content uniformity detection method of the benidipine hydrochloride tablets in the Japanese pharmacopoeia is that 1 tablet of a sample is shaken until the benidipine hydrochloride is dissolved. The benidipine hydrochloride tablet is a coated tablet, so that the active ingredients of the coating layer can be dissolved by shaking for a long time, the detection time is long, and the benidipine hydrochloride tablet is not suitable for daily operation.
4. The benidipine hydrochloride has two crystal forms of alpha and beta, and has alpha type with pharmacological action. The chromatographic peak of the beta isomer is adjacent to the active ingredient, and improper selection of chromatographic conditions can cause the isomer to be combined with the main ingredient, thus causing high results.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and provides a method for measuring the content uniformity of benidipine hydrochloride tablets, which is simple to operate, reliable in method, high in repeatability and high in accuracy and is verified by methodology according to the characteristics of the benidipine hydrochloride tablets.
The technical scheme adopted by the invention for solving the technical problem is as follows:
a method for measuring content uniformity of benidipine hydrochloride tablets comprises the following steps: taking 1 tablet of benidipine hydrochloride, placing in a 100ml measuring flask, adding a proper amount of methanol-diluted phosphoric acid mixed solution, ultrasonically dissolving and diluting benidipine hydrochloride to scale, shaking up, filtering, and taking the subsequent filtrate as a test solution.
Preferably, the concentration of the dilute phosphoric acid is 0.2%, and the volume ratio of the methanol to the dilute phosphoric acid is 1: 1.
Preferably, the steps further comprise: and (3) measuring the test solution by using a high performance liquid chromatography, wherein the chromatographic conditions and the system applicability test are as follows: chromatographic column using octadecylsilane chemically bonded silica as filler; using 0.05mol/L potassium dihydrogen phosphate solution (pH is adjusted to 3.0 by phosphoric acid) -methanol-tetrahydrofuran as mobile phase; detecting wavelength at 237nm, column temperature at 25 deg.C, adjusting flow rate to make peak retention time of benidipine hydrochloride about 20min, precisely measuring 10 μ l of filtrate, injecting into liquid chromatograph, and recording chromatogram;
taking another appropriate amount of benidipine hydrochloride reference substance, precisely weighing, dissolving with the above mixed solution, quantitatively diluting to obtain solution containing 0.08mg per 1ml, and determining by the same method;
calculating according to the peak area by an external standard method to obtain the product.
Preferably, the column is an Agilent Pursuit, 4.6X 100mm, 3 μm or equivalent performance column.
Preferably, the mobile phase is a 0.05mol/L solution of potassium dihydrogen phosphate (pH adjusted to 3.0 with phosphoric acid) -methanol-tetrahydrofuran volume ratio of 65:27: 8.
The invention has the beneficial effects that:
compared with the prior art, the method for measuring the content uniformity of the benidipine hydrochloride tablets is simple to operate, reliable, small in influence on human health, high in repeatability and high in accuracy through methodology verification.
Detailed Description
The present invention will be further described with reference to specific examples to assist understanding of the invention. The method used in the invention is a conventional production method if no special provisions are made; the starting materials used, unless otherwise specified, are conventional commercial products.
Examples
A method for measuring content uniformity of benidipine hydrochloride tablets comprises the following steps:
taking 1 tablet of benidipine hydrochloride, placing in a 100ml measuring flask, adding a proper amount of methanol-diluted phosphoric acid mixed solution, ultrasonically dissolving and diluting benidipine hydrochloride to scale, shaking up, filtering, and taking the subsequent filtrate as a test solution.
The concentration of the dilute phosphoric acid is 0.2 percent, and the volume ratio of the methanol to the dilute phosphoric acid is 1: 1.
And (3) measuring the test solution by using a high performance liquid chromatography, wherein the chromatographic conditions and the system applicability test are as follows: a column packed with octadecylsilane bonded silica gel (Agilent Pursuit, 4.6X 100mm, 3 μm or equivalent performance column); using 0.05mol/L potassium dihydrogen phosphate solution (pH is adjusted to 3.0 by phosphoric acid) -methanol-tetrahydrofuran (65: 27: 8) as a mobile phase; detecting wavelength at 237nm, column temperature at 25 deg.C, adjusting flow rate to make peak retention time of benidipine hydrochloride about 20min, precisely measuring 10 μ l of filtrate, injecting into liquid chromatograph, and recording chromatogram;
taking another appropriate amount of benidipine hydrochloride reference substance, precisely weighing, dissolving with the above mixed solution, quantitatively diluting to obtain solution containing 0.08mg per 1ml, and determining by the same method;
the content of each tablet is obtained by calculating the peak area according to an external standard method, the content average value of the content uniformity of the benidipine hydrochloride tablet is 98.9 percent of the marked amount, the RSD value is 0.89 percent, the content average value meets the specification, the establishment of the method is verified through methodology, and the method is high in repeatability and accuracy.
In conclusion, compared with the prior art, the method for measuring the content uniformity of the benidipine hydrochloride tablets is simple to operate and reliable, and has high repeatability and high accuracy through methodology verification.
However, the above description is only an embodiment of the present invention, and the scope of the present invention should not be limited by this, and all equivalent changes and modifications made in the claims of the present invention should be covered by the present invention.
Claims (5)
1. A method for measuring content uniformity of benidipine hydrochloride tablets is characterized by comprising the following steps: taking 1 tablet of benidipine hydrochloride, placing in a 100ml measuring flask, adding a proper amount of methanol-diluted phosphoric acid mixed solution, ultrasonically dissolving and diluting benidipine hydrochloride to scale, shaking up, filtering, and taking the subsequent filtrate as a test solution.
2. The method for determining the content uniformity of the benidipine hydrochloride tablets as claimed in claim 1, wherein the concentration of the dilute phosphoric acid is 0.2%, and the volume ratio of the methanol to the dilute phosphoric acid is 1: 1.
3. The method for measuring the content uniformity of the benidipine hydrochloride tablets according to claim 1, wherein the method further comprises the following steps: and (3) measuring the test solution by using a high performance liquid chromatography, wherein the chromatographic conditions and the system applicability test are as follows: chromatographic column using octadecylsilane chemically bonded silica as filler; using 0.05mol/L potassium dihydrogen phosphate solution (pH is adjusted to 3.0 by phosphoric acid) -methanol-tetrahydrofuran as mobile phase; detecting wavelength at 237nm, column temperature at 25 deg.C, adjusting flow rate to make peak retention time of benidipine hydrochloride about 20min, precisely measuring 10 μ l of filtrate, injecting into liquid chromatograph, and recording chromatogram;
taking another appropriate amount of benidipine hydrochloride reference substance, precisely weighing, dissolving with the above mixed solution, quantitatively diluting to obtain solution containing 0.08mg per 1ml, and determining by the same method;
calculating according to the peak area by an external standard method to obtain the product.
4. The method for measuring the content uniformity of the benidipine hydrochloride tablets as claimed in claim 3, wherein the chromatographic column is an Agilent Pursuit, 4.6 x 100mm, 3 μm or equivalent performance chromatographic column.
5. The method for measuring content uniformity of the benidipine hydrochloride tablet as claimed in claim 3, wherein the volume ratio of 0.05mol/L potassium dihydrogen phosphate solution (adjusted to pH 3.0 with phosphoric acid) in the mobile phase to methanol-tetrahydrofuran is 65:27: 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973392.2A CN112730714A (en) | 2019-10-14 | 2019-10-14 | Method for measuring content uniformity of benidipine hydrochloride tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973392.2A CN112730714A (en) | 2019-10-14 | 2019-10-14 | Method for measuring content uniformity of benidipine hydrochloride tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112730714A true CN112730714A (en) | 2021-04-30 |
Family
ID=75588438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910973392.2A Pending CN112730714A (en) | 2019-10-14 | 2019-10-14 | Method for measuring content uniformity of benidipine hydrochloride tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112730714A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114324651A (en) * | 2021-12-28 | 2022-04-12 | 苏州东瑞制药有限公司 | Method for detecting methyl acetoacetate in benidipine hydrochloride |
-
2019
- 2019-10-14 CN CN201910973392.2A patent/CN112730714A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114324651A (en) * | 2021-12-28 | 2022-04-12 | 苏州东瑞制药有限公司 | Method for detecting methyl acetoacetate in benidipine hydrochloride |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101788469A (en) | Method for online detecting near infrared spectrum of active ingredients of compound eucommia bark capsules | |
| CN106706785A (en) | Method for detecting related substances in irbesartan hydrochlorothiazide tablets by adopting high performance liquid chromatography | |
| CN109633063B (en) | Method for detecting concentration of ticagrelor and active metabolite thereof in human plasma | |
| CN110954603A (en) | Method for determining rivaroxaban and related substances thereof by using high performance liquid chromatography | |
| CN104597171A (en) | High performance liquid chromatography analysis method of acarbose and its preparation | |
| CN112730714A (en) | Method for measuring content uniformity of benidipine hydrochloride tablets | |
| CN113866328A (en) | Screening method for cross-scene non-marking-liquid autonomous recognition of illegally added drugs | |
| CN106706769B (en) | Separation and determination method of empagliflozin and optical isomer thereof | |
| CN109975448A (en) | A kind of detection method of dabigatran etexilate methanesulfonate or its preparation in relation to substance or/and content | |
| CN101390984B (en) | Detection method of Lanhuayao | |
| CN104297354B (en) | The detection method of impurity in a kind of high effective liquid chromatography for measuring amyl ethyl quin ether hydrochloride | |
| CN110412164B (en) | Method for detecting related substances of mexiletine hydrochloride | |
| CN107490629A (en) | A kind of HPLC analytical method of afatinib intermediate | |
| CN114324642A (en) | Method for determining dextromethorphan hydrobromide related substances | |
| CN103063765A (en) | Detecting method for ligustrazine hydrochloride in salvia miltiorrhiza and ligustrazine glucose injection | |
| CN115248260A (en) | HPLC analysis detection method for related substances in cisatracurium besilate bulk drug | |
| CN112730713A (en) | Method for detecting impurities in benidipine hydrochloride tablets | |
| CN116338025A (en) | Method for measuring N-nitrosovalinamide by liquid chromatography-mass spectrometer | |
| CN114660213B (en) | Component content determination method of compound reserpine hydrochlorothiazide tablet | |
| CN113092632B (en) | Method for detecting content of dehydroandrographolide in Chuanwang anti-inflammatory tablet | |
| Raza et al. | Spectrophotometric determination of citalopram hydrobromide in tablet dosage form using chloranil | |
| Koduru et al. | Stability-indicating RP-HPLC method applied to the quantification of anti-histaminic drug ebastine in its oral suspension dosage form | |
| CN103675149A (en) | Method for detecting ligustrazine in salviae miltiorrhizae and ligusticum wallichii glucose injection | |
| CN114264749A (en) | Analysis and detection method of dabigatran etexilate | |
| CN112730715A (en) | Method for detecting dissolution rate of benidipine hydrochloride tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |